You are here

Black Patients With Kidney Cancer Have Poorer Survival Than Whites

NCI study finds 68% and 73% 5-year survival rates, respectively (Nov. 12)

Since the mid-1990s, black Americans have had a higher incidence of renal cell carcinoma, the most common form of kidney cancer, than white Americans. Research also suggests that racial disparities exist in the survival of patients with renal cell carcinoma, with black patients dying earlier than whites.

When Wong-Ho Chow, PhD, and her colleagues at the National Cancer Institute (NCI) analyzed national data from nearly 40,000 renal-cell carcinoma patients, they confirmed the poorer survival rates for black patients compared with whites. Specifically, 72.6% of white patients survived for at least 5 years, compared with 68.0% of black patients. The survival advantage of white patients over black patients was consistently seen in all subgroups of patients, regardless of gender, age, tumor stage or size, tumor subtype, or type of surgical treatment.

Surprisingly, a higher percentage of black patients than white patients were diagnosed at the localized stage, with smaller tumors, or with a less aggressive subtype of cancer. These factors should indicate a better prognosis. Also, compared with white patients, a slightly higher percentage of black patients received no surgical treatment, which is associated with a substantially poorer prognosis.

“We cannot rule out the possibility that other factors not measured in our study — such as obesity, high blood pressure, access to care, and genetic susceptibility — may be contributing to the persistent disparities,” Chow said.

Source: Wiley; November 12, 2012.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs